CA2158869A1 - Virus recombinants, preparation et utilisation en therapie genique - Google Patents

Virus recombinants, preparation et utilisation en therapie genique

Info

Publication number
CA2158869A1
CA2158869A1 CA002158869A CA2158869A CA2158869A1 CA 2158869 A1 CA2158869 A1 CA 2158869A1 CA 002158869 A CA002158869 A CA 002158869A CA 2158869 A CA2158869 A CA 2158869A CA 2158869 A1 CA2158869 A1 CA 2158869A1
Authority
CA
Canada
Prior art keywords
preparing
same
gene therapy
recombinant virus
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002158869A
Other languages
English (en)
Other versions
CA2158869C (fr
Inventor
Hedi Haddada
Evelyne May
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hedi Haddada
Evelyne May
Michel Perricaudet
Rhone-Poulenc Rorer S.A.
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9304745A external-priority patent/FR2704234B1/fr
Application filed by Hedi Haddada, Evelyne May, Michel Perricaudet, Rhone-Poulenc Rorer S.A., Aventis Pharma S.A. filed Critical Hedi Haddada
Publication of CA2158869A1 publication Critical patent/CA2158869A1/fr
Application granted granted Critical
Publication of CA2158869C publication Critical patent/CA2158869C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des adénovirus recombinants comportant une séquence d'ADN hétérologue, leur préparation, et leur utilisation pour le traitement et/ou la prévention des cancers.
CA002158869A 1993-04-22 1994-04-15 Virus recombinants, preparation et utilisation en therapie genique Expired - Lifetime CA2158869C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR93/04745 1993-04-22
FR9304745A FR2704234B1 (fr) 1993-04-22 1993-04-22 Virus recombinants, preparation et utilisation en therapie genique.
PCT/FR1994/000421 WO1994024297A1 (fr) 1993-04-22 1994-04-15 Adenovirus recombinants defectifs pour la therapie genique des tumeurs

Publications (2)

Publication Number Publication Date
CA2158869A1 true CA2158869A1 (fr) 1994-10-27
CA2158869C CA2158869C (fr) 2007-07-03

Family

ID=38246505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002158869A Expired - Lifetime CA2158869C (fr) 1993-04-22 1994-04-15 Virus recombinants, preparation et utilisation en therapie genique

Country Status (1)

Country Link
CA (1) CA2158869C (fr)

Also Published As

Publication number Publication date
CA2158869C (fr) 2007-07-03

Similar Documents

Publication Publication Date Title
TW260708B (fr)
CA2011878A1 (fr) Regions immunogenes sur la proteine e7 du papillomavirus humain de type 16
ZA963863B (en) Recombinant viral vector system.
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FR2716682B1 (fr) Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
CA2050304A1 (fr) Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
CA2000786A1 (fr) 3-piperidinyl-1,2-benzisoxazoles
EP1005376A4 (fr) Methodes et compositions utilisees en therapie genique dans le traitement de l'hemophilie
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
CA2165821A1 (fr) Oligonucleotides antisens et utilisation therapeutique de ceux-ci dans l'infection par le virus de l'immunodeficience humaine
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ES2012129A6 (es) Un metodo para la obtencion de fragmentos de cd4 humana biologicamenteactivos.
FR2730504B1 (fr) Procede de preparation de genomes d'adenovirus recombinants
FR2751658B1 (fr) Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
CA2155017A1 (fr) Fonction proteinique vpr et activite de celle-ci
WO1996031607A3 (fr) Utilisation d'une lymphokine pour inhiber la replication de virus et, en particulier, de retrovirus, provoquant une immunodeficience
EP0868522A4 (fr) Virus de recombinaison combine de la variole et de la peritonite infectieuse du chat, compositions le contenant et leurs procedes d'obtention et d'utilisation
ZA873338B (en) Process for isolating and purifying p. falciparium cs protein vaccine expressed in recombinant e. coli
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
CA2158869A1 (fr) Virus recombinants, preparation et utilisation en therapie genique
EP0110791A3 (en) Peptides containing an immunogenic site of the poliovirus, and dna's containing nucleotide fragments encoding for these peptides
EP0254593A3 (fr) Préparation et applications d'interféron gamma
CA2184297A1 (fr) Virus recombinants codant pour une activite glutamate decarboxylase (gad)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140415